Durvalumab vs Lansoprazole
Durvalumab vs Lansoprazole: Overview
This comparison examines the pharmacological differences between Durvalumab and Lansoprazole.
Mechanism of Action
Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.
Lansoprazole: Proton pump inhibitor.
Pharmacokinetics
Half-life: Durvalumab β 17 days; Lansoprazole β 1.5 hours.
Chemical Properties
Molecular Formula: Lansoprazole β C16H14F3N3O2S.
Molecular Weight: Lansoprazole β 369.3620 g/mol.
Type: Durvalumab β Antibody; Lansoprazole β Small molecule.